Robert W. Baird Cuts Boston Scientific (NYSE:BSX) Price Target to $78.00

Boston Scientific (NYSE:BSX) had its price objective cut by Robert W. Baird from $86.00 to $78.00 in a report released on Thursday morning, MarketBeat.com reports. They currently have an outperform rating on the medical equipment provider’s stock.

BSX has been the topic of a number of other research reports. Barclays cut their price objective on shares of Boston Scientific from $124.00 to $100.00 and set an “overweight” rating on the stock in a research report on Wednesday. Raymond James Financial restated an “outperform” rating and issued a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Jefferies Financial Group cut their price target on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $115.00 price target on shares of Boston Scientific in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $93.91.

Boston Scientific Trading Down 5.6%

BSX stock opened at $62.01 on Thursday. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific has a twelve month low of $59.38 and a twelve month high of $109.50. The stock has a market capitalization of $92.16 billion, a price-to-earnings ratio of 25.95, a price-to-earnings-growth ratio of 1.08 and a beta of 0.78. The firm’s fifty day simple moving average is $68.45 and its two-hundred day simple moving average is $85.71.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the business posted $0.75 earnings per share. The business’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts anticipate that Boston Scientific will post 3.37 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.34% of the stock is currently owned by company insiders.

Institutional Trading of Boston Scientific

Hedge funds have recently added to or reduced their stakes in the business. Financial Consulate Inc. purchased a new stake in Boston Scientific in the third quarter worth about $25,000. Murphy & Mullick Capital Management Corp lifted its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC purchased a new stake in Boston Scientific in the second quarter worth about $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the fourth quarter worth about $26,000. Finally, Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific in the fourth quarter worth about $26,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat consensus — revenue grew ~11.6% and EPS topped estimates, showing underlying demand and execution that underpinned an initial share pop after the report. Boston Scientific Corporation (NYSE:BSX) Q1 2026 Earnings Call Transcript
• Positive Sentiment: Unusual call-option activity — heavy call buying was reported around the earnings period, indicating some traders are positioning for a rebound or event-driven upside. Traders Purchase High Volume of Boston Scientific Call Options (NYSE:BSX)
• Neutral Sentiment: Analyst views are mixed and the investment story is being reset — several coverage teams trimmed fair-value estimates and split between seeing a buy opportunity versus emphasizing execution risk. This creates divergence in short‑to‑medium term expectations. How The Investment Story Is Resetting For Boston Scientific (BSX) After Recent Analyst Shifts
• Negative Sentiment: Company trimmed 2026 profit and revenue outlook — management lowered full‑year guidance (Q2 trough flagged), which directly reduced near‑term earnings visibility and is the primary driver of the pullback. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Analysts slashed price targets after Q1/guidance — multiple firms trimmed targets (Truist, Baird, Needham, others), which amplifies selling pressure and reduces near‑term analyst support. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Negative Sentiment: Multiple securities‑class action notices and law‑firm solicitations — several firms are soliciting lead‑plaintiff candidates tied to a July 2025–Feb 2026 class period, increasing legal risk and potential headline volatility. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Downgrades and new 52‑week low headlines — coverage noting downgrades and a 52‑week low contributes to technical selling and stops being hit. Boston Scientific (NYSE:BSX) Hits New 52-Week Low After Analyst Downgrade

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.